Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab
Germany’s Stada Arzneimittel (SAZ: GR) and Hungarian group Gedeon Richter (BDP: RICHTER) have signed two separate license and collaboration agreements for the development and marketing of two biosimilar products for the two monoclonal antibodies - rituximab and trastuzumab.
Rituximab is Swiss drug major Roche’s (ROG: SXI) best-selling Rituxan/MabThera for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arthritis, which contributed 3.06 billion Swiss francs ($3.77 billion in first half 2011 sales, and a copy of which is already under development by Sandoz (The Pharma Letter January 11). Trastuzumab is Roche’s breast cancer drug Herceptin, which had first half turnover of 2.72 billion francs. The Swiss firm recently entered into a three-year agreement with R-Farm to market the drug in Russia, where the oncology drug market is estimated at $4-$5 billion a year at present (TPL June 23).
Rights cover Europe and CIS
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze